Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich F P
Osaka Prefectural Institute of Public Health, Japan.
J Pharmacol Exp Ther. 1994 Jul;270(1):414-23.
Interindividual variations in the level and activity of cytochrome P-450 enzymes were investigated in the liver microsomes of 30 Japanese and 30 Caucasian patients. The P-450 enzymes used in this study included P-450 1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A, and the monooxygenase activities determined were 13 typical P-450 substrates and 9 procarcinogens. Although the total P-450 content was higher in Caucasian (mean, 0.43 nmol/mg of protein) than in Japanese populations (mean, 0.26 nmol/mg of protein), the relative levels (percent of total P-450) of individual forms of P-450 determined immunochemically were not very different except that P-450 2A6 and 2B6 levels were higher in the Caucasians. About 70% of liver P-450 could be accounted for by P-450 1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A proteins, and P-450 3A (about 30% of total P-450) and 2C (about 20%) enzymes were found to be the major forms. Considerable levels of P-450 1A2 (about 13%) and 2E1 (about 7%) could be determined, whereas the P-450 2A6 (about 4%), 2D6 (about 2%) and 2B6 (< 1%) were the minor P-450 forms. Differences in some of the P-450 1A2-, 2A6-, 2D6-, 2E1- and 3A4-dependent activities were observed in Japanese and Caucasian populations. No clear sex-related differences in individual P-450 contents and drug- and carcinogen-metabolizing activities were detected in 60 human samples, except that P-450 1A2-dependent activities were found to be higher in mean than in women in the Caucasian population only. A single neonate sample tended to be lower in P-450 1A2-, 2A6- and 2E1-dependent activities. In contrast to rat counterparts, we could not detect apparent developmental changes in P-450 content and activity in humans between 12 and 73 years old. Thus, the results presented in this study provide useful information for the study of drug biotransformation in humans and for the basis of drug toxicities, carcinogenesis and teratogenesis.
在30名日本患者和30名高加索患者的肝脏微粒体中研究了细胞色素P - 450酶水平和活性的个体间差异。本研究中使用的P - 450酶包括P - 450 1A2、2A6、2B6、2C、2D6、2E1和3A,所测定的单加氧酶活性针对13种典型的P - 450底物和9种前致癌物。尽管高加索人(平均0.43 nmol/mg蛋白质)的总P - 450含量高于日本人群(平均0.26 nmol/mg蛋白质),但通过免疫化学测定的各种P - 450个体形式的相对水平(占总P - 450的百分比)差异不大,只是高加索人中P - 450 2A6和2B6的水平较高。肝脏中约70%的P - 450可由P - 450 1A2、2A6、2B6、2C、2D6、2E1和3A蛋白来解释,发现P - 450 3A(约占总P - 450的30%)和2C(约占20%)酶是主要形式。可测定到相当水平的P - 450 1A2(约13%)和2E1(约7%),而P - 450 2A6(约4%)、2D6(约2%)和2B6(<1%)是次要的P - 450形式。在日本人和高加索人群中观察到了一些P - 450 1A2、2A6、2D6、2E1和3A4依赖性活性的差异。在60份人类样本中未检测到个体P - 450含量以及药物和致癌物代谢活性方面明显的性别相关差异,只是仅在高加索人群中发现P - 450 1A2依赖性活性平均而言男性高于女性。单个新生儿样本的P - 450 1A2、2A6和2E1依赖性活性往往较低。与大鼠不同,在12至73岁的人类中未检测到P - 450含量和活性明显的发育变化。因此,本研究结果为人类药物生物转化研究以及药物毒性、致癌作用和致畸作用的研究提供了有用信息。